However, the combination of anti-TNF and thiopurine therapy increased the risk of benign infections in infants compared with anti-TNF monotherapy alone.[4,19–21] Because infliximab can be detected in infants up to 12 months after delivery,[4] there is some concern about the effect on the immune system, rate of infection, and response to vaccines, especially with living organisms. Here, TNF is linked to neoplasm.